I wonder if more capital is needed to run some more trials. The...

I wonder if more capital is needed to run some more trials. The interesting part is going to be what the money is earmarked for and if we have any new institutional shareholders coming onboard.

I can understand then raising at this market cap - the dilution should be small but going to be interesting to see the amount.

Part of me also wonders if we need to do this to flush out commercials partners / acquisition offers. If we can’t make a credible case that we can run a lot of the trials ourselves, we comprise our negotiating position for the best deal.

there’s going to be a lot to unpick once we see the specifics

cheers,

YS